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Background: There is a significant public health burden associated with substance use in Canada. The early
detection and/or treatment of risky substance use has the potential to dramatically improve outcomes for those
who experience harms from the non-medical use of psychoactive substances, particularly adolescents whose brains
are still undergoing development. The Screening, Brief Intervention, and Referral to Treatment model is a
comprehensive, integrated approach for the delivery of early intervention and treatment services for individuals
experiencing substance use-related harms, as well as those who are at risk of experiencing such harm.
Methods: This article describes the protocol for a systematic review of the effectiveness of brief interventions as
part of the Screening, Brief Intervention, and Referral to Treatment model for reducing the non-medical use of
psychoactive substances. Studies will be selected in which brief interventions target non-medical psychoactive
substance use (excluding alcohol, nicotine, or caffeine) among those 12 years and older who are opportunistically
screened and deemed at risk of harms related to psychoactive substance use. We will include one-on-one verbal
interventions and exclude non-verbal brief interventions (for example, the provision of information such as a
pamphlet or online interventions) and group interventions. Primary, secondary and adverse outcomes of interest are
prespecified. Randomized controlled trials will be included; non-randomized controlled trials, controlled before-after
studies and interrupted time series designs will be considered in the absence of randomized controlled trials. We
will search several bibliographic databases (for example, MEDLINE, EMBASE, CINAHL, PsycINFO, CORK) and search
sources for grey literature. We will meta-analyze studies where possible. We will conduct subgroup analyses,
if possible, according to drug class and intervention setting.
Discussion: This review will provide evidence on the effectiveness of brief interventions as part of the Screening,
Brief Intervention, and Referral to Treatment protocol aimed at the non-medical use of psychoactive substances and
may provide guidance as to where future research might be most beneficial.
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We used the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses for Protocols (PRISMA-P)
checklist to guide the reporting of this protocol [1].
According to the 2010 Canadian Alcohol and Drug Use
Monitoring Survey [2], 11.2% of Canadians aged 15 years
and older reported past-year use of at least one of the
following psychoactive substances: cannabis, cocaine/
crack, methamphetamine/crystal methamphetamine, ec-
stasy, hallucinogens, salvia, inhalants, heroin, pain relie-
vers, stimulants or sedatives. The rate of past-year use of
any of these substances was higher among males than
females (15.3% versus 7.5%, respectively). Rates were also
higher among those aged 15- to 24-years-old compared
with adults 25 years and older (26.3% versus 8.3%, respect-
ively). Furthermore, among those reporting past-year use,
17% reported experiencing substance use-related harm.
There is also a significant public health burden asso-
ciated with substance use in Canada. According to 2002
estimates, substance abuse costs Canadians close to $40
billion ($1,267 per Canadian), with use of psychoactive
substances (excluding alcohol) accounting for approxi-
mately $8.2 billion (20.7%) of the total costs [3]. The vast
majority of those costs are associated with Canadians’
lost productivity and health.
For the purpose of this review, non-medical psychoactive
substance use includes the use of drugs prohibited by
international law including, but not limited to, amphet-
amine-type stimulants, cannabis, cocaine, heroin and 3,4-
methylenedioxymethamphetamine (MDMA) [4]; the non-
medical use of pharmaceuticals such benzodiazepines,
opioids or dextromethorphan; and the use of substances
such as solvents or inhalants (for example, gasoline, acet-
one) when they are used for their intoxicating effects. It
does not include alcohol, nicotine or caffeine.
The early detection and/or treatment of risky substance
use has the potential to dramatically improve outcomes for
those who experience harms from the non-medical use of
psychoactive substances, particularly adolescents whose
brains are still undergoing development. Screening, Brief
Intervention, and Referral to Treatment (SBIRT) is a com-
prehensive, integrated approach to the delivery of early
intervention and treatment services for individuals experi-
encing substance use-related harms, as well as those who
are at risk of experiencing such harms [5]. The SBIRT
model is based on public health principles and procedures,
and is designed to reduce the burden of injury, disease and
disability associated with the non-medical use of psycho-
active substances.
The protocol typically begins with a screening proced-
ure that involves asking questions to evaluate whether
the individual has experienced, or is at risk of experien-
cing, substance use-related harms. Brief interventions
(BIs) are typically delivered to those individuals at low tomoderate risk of harms; individuals identified as experi-
encing significant harm and/or having more serious signs
of substance dependence warranting formal diagnosis
may be referred to treatment services that are outside
the scope of BIs.
Screening
To evaluate the likelihood that an individual is experien-
cing, or is at risk of experiencing, substance use-related
harms, individuals are screened. Screening may be con-
ducted in a number of different ways. For example, screen-
ing may be conducted via psychometrically validated
questionnaires or tests developed to accurately categorize
users into low, moderate, and high risk categories. Such
tests have been developed for different types of substances
such as alcohol (Alcohol Use Disorders Identification Test
[6]), cannabis (the Cannabis Use Disorders Identification
Test [7]) or prescription opioids (for example, the Opioid
Risk Tool [8]). General drug screening tests also exist (for
example, the Drug Abuse Screening Test [9]). However,
screening tests that reliably categorize users into low or
moderate risk groups have not been developed for other
substances (for example, heroin and cocaine). For these
substances, screening may simply take the form of self-
reported use or biological markers indicating use (such as
hair, urine, oral fluid or blood) rather than psychometric-
ally validated self-report instruments. In the absence of
validated tests or biological markers, others may rely on
even less rigorous screening methods, such as the subject-
ive judgment of the individual conducting the assessment.
Regardless of the screening method employed, those
deemed at risk of harms are typically provided a BI or
referred to treatment. In cases where self-reported use or
biological markers indicating use are used for screening, it
is unclear how practitioners make the decision whether to
administer a BI versus referral to treatment.
In reviews where the effectiveness of SBIRT models in
reducing harms associated with alcohol use have been
evaluated systematically [10-12], few protocols have
employed a rigid definition of the screening criteria used
to determine whether a BI was administered. This is
likely a result of two factors: poor descriptions of screen-
ing procedures employed in studies reviewed and/or the
heterogeneity of screening procedures employed.
Brief intervention
In addition to the variability in screening procedures
employed, there is also much variation in how BIs are
defined and delivered. In general, BIs are in-person, time-
limited efforts to provide information or advice, increase
motivation to avoid substance use, or to teach behavior
change skills with the aim of reducing substance use and
the likelihood of experiencing negative consequences. This
variation includes the number of conversations or meetings
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amount of time spent conducting the BI. Reviews such as
Kaner et al. [11] have defined ‘brief ’ to mean four or less
and note that BIs for alcohol that are provided in primary
health care settings are typically delivered within the nor-
mal consultation period of 5 to 30 minutes. Levy et al. [13]
suggest that successful BIs typically focus on the following
elements (collectively referred to using the acronym
FRAMES): feedback on behavior and consequences;
responsibility to change; advice; menu of options to bring
about change; empathy; and self-efficacy for change.
There is substantial scientific evidence of the benefits of
the SBIRT model in primary health care settings as a means
to address the harms associated with alcohol use [14-16].
This evidence suggests the SBIRT process can serve as an
effective ‘early warning’ system to prevent and/or reduce
the serious long-term harms associated with excessive alco-
hol use. A corresponding analysis for SBIRT targeting the
non-medical use of other psychoactive substances is
needed.
There is accumulating evidence suggesting that BIs may
be effective in reducing the non-medical use of psycho-
active substances, such as cannabis [17-21], ecstasy [22],
cocaine [18,23,24], benzodiazepines [25] and opioids
[6,13,23] among both youths and adults. Traditionally, the
SBIRT model has been implemented in primary care set-
tings, emergency departments, inpatient trauma units and
other health care settings. These settings see the broadest
number and range of patients and thus provide ideal
opportunities to screen for, and address, substance use be-
fore more severe consequences occur [26]. More recently,
however, the protocol is being applied in schools [21,27]
and community settings [22] in an attempt to reach young
people. It is unclear whether the effectiveness of the SBIRT
approach is dependent on the setting in which it is applied.
The diversity of substances used and the high prevalence
of use and dependence have raised some concerns about
the efficacy of a SBIRT protocol for substances other than
alcohol [26]. Individuals who use more than one substance
or use alcohol and other substances make administering
and evaluating SBIRT more complicated than when
addressing alcohol alone [28]. Substances have variable
forms, costs, risks, consequences and ways for clinicians to
identify use. Moreover, most psychoactive substances that
are used without medical supervision are illegal or used il-
legally, which can complicate addressing their use in med-
ical settings by raising patient and physician concerns
about confidentiality. Prescription drug misuse presents
additional challenges as clinicians struggle to distinguish
between appropriate and inappropriate use.
Objectives
This systematic review will determine the effects of BIs,
as part of the SBIRT protocol, on reducing substance usein adolescents and adults identified as experiencing, or at
risk of experiencing, harms related to the non-medical
use of psychoactive substances (excluding alcohol,
caffeine and nicotine). In addition, potential moderating





Studies in which BIs are administered to adolescents (12
to 18 years of age or equivalent by level of schooling),
young adults (19 to 24 years of age), or adults (25 years
and older) at risk of harms related to psychoactive sub-
stance use as determined by the screening component of
the SBIRT protocol will be included. We will exclude
studies evaluating interventions targeting children less
than 12 years of age.
Screening
Screening must be opportunistic in nature (that is, it must
be conducted among a population not seeking treatment
for substance use) and is defined as any procedure or
method used to identify those experiencing or at risk of
harms associated with the non-medical use of psychoactive
substances. This may include, but is not limited to, ques-
tions regarding the use of substances, the use of psycho-
metrically validated scales, or biological (for example,
blood, hair, urine, oral fluid) screening tools. We will
exclude studies failing to indicate they used a method of
screening to determine who receives a BI.
Brief intervention
BIs are time-limited efforts to provide information or ad-
vice, increase motivation to avoid substance use, or to
teach behavioral change skills with the aim of reducing
substance use and the likelihood of experiencing negative
consequences.
We will include studies in which BIs target non-medical
psychoactive substance use. This includes the use of drugs
prohibited by international law including, but not limited
to: amphetamine-type stimulants, cannabis, cocaine, her-
oin and MDMA [4]; the non-medical use of pharmaceuti-
cals such benzodiazepines, opioids or dextromethorphan;
and the use of substances such as solvents or inhalants
(for example, gasoline, acetone) when they are used for
their intoxicating effects. We will exclude studies in which
the BI only targets alcohol, nicotine or caffeine use. In
addition, interventions that do not provide feedback on at
least one of the FRAMES elements or provide five or more
sessions [11] will be excluded.
For the current review we will only examine one-on-one
verbal interventions and exclude non-verbal BIs (for ex-
ample, the provision of information such as a pamphlet or
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interventions differ sufficiently from verbal one-on-one.
However, we will collate studies assessing the effectiveness
of online and group interventions and report on the search
yield in the review.
Referral to treatment
We will not address the effectiveness of the referral to
treatment component of the SBIRT protocol in this
review.
Comparisons
Studies comparing BI to no BI, provision of pamphlets
or other information only, or delayed intervention will
be included. Studies without a comparison or control
group will be excluded.
Outcomes
We will evaluate the outcomes listed below for any
period of follow-up.
Primary outcomes:
1. Substance use versus non-use.
2. Frequency and quantity of use.
3. Any standard or accepted biological markers of
substance use (for example, blood, oral fluid).
4. Self- or other reported use-related harms or negative
consequences of use.
5. Self- or other reported changes in behavior likely to
result in the reduction of negative substance use-
related consequences.
6. Decision to attend treatment.
Secondary outcomes:
1. Use of different substances from that for which the
client received the BI (including use of alcohol,
caffeine, or nicotine) as assessed by self- or other
reported or biological markers substance use.
2. Self- or other reported intention to reduce substance
use.
3. Self- or other reported health measure.
Adverse outcomes:
1. Self- or other reported use or increased use of
different substances from that for which the client
received the BI as assessed by self- or other reported
or biological markers substance use.
2. Other adverse outcomes.
Settings
We will include studies that use opportunistic screening
regardless of location, including, but not limited to,primary health care, emergency room, school and other
community settings.
Study designs
All randomized controlled trials (RCTs) will be included,
including any cluster RCTs. Where RCTs are lacking or,
for issues relating to feasibility, not conducted, non-
RCTs, controlled before-after studies and interrupted
time series designs will be considered. These latter
designs will include some form of control group, whether
concurrent or within-patient. Interrupted time series
studies must have a clearly defined time point at which
the intervention is introduced and at least three data
points before and after introducing the intervention;
those ignoring secular changes and performing simple
pre-post analyses will not be included unless re-analysis
is possible [29]. We will not evaluate retrospective stud-
ies or studies with historical controls. We will exclude
comments, letters and editorials.
Search methods
Electronic bibliographic databases
A comprehensive literature search for studies and sys-
tematic reviews using high recall subject searches will be
conducted using several electronic databases: MEDLINE,
EMBASE, The Cochrane Library, Cumulative Index to
Nursing and Allied Health Literature (CINAHL), Psy-
cINFO, Education Resources Information Center (ERIC)
and the CORK Database. All electronic search strategies
will be peer-reviewed using the PRESS tool prior to im-
plementation [30]. The proposed MEDLINE search strat-
egy is shown in Appendix 1; the search will be adapted
to the other databases.
Other sources
‘Grey literature’ searches will be conducted for other po-
tentially relevant studies. Websites of health technology
assessment and evidence-based review organizations as
listed in Grey Matters: a practical tool for evidence-based
searching [31] will be searched as well as PsycEXTRA.
Websites of relevant organizations, such as the Canadian
Centre on Substance Abuse, Centre for Addiction and
Mental Health, the Substance Abuse and Mental Health
Services Administration, National Institute for Drug
Abuse and the Centre for Addictions Research British
Columbia, as well as those indicated on the Substance
Abuse Librarians & Information Specialists site will be
searched. We will also access the websites of specific orga-
nizations, such as the College of Physicians and Surgeons
of Ontario. We will consult within our internal team to
identify additional studies that may not be in the published
literature. We will search the Campbell Collaboration for
systematic reviews. We will scan bibliographies of included
articles and relevant systematic reviews. We will consult
Young et al. Systematic Reviews 2012, 1:22 Page 5 of 11
http://www.systematicreviewsjournal.com/content/1/1/22clinicaltrials.gov and the WHO International Clinical
Trials Registry Platform for ongoing studies.
Language
We will not restrict our search based on language but will
only include articles available in the English and French
languages. A list of the possibly relevant titles available in
other languages will be provided as an appendix.
Study selection
The results of the literature search will be assessed using
a two-step process. First, one individual will screen cita-
tions by title and/or abstract according to the prespeci-
fied screening questions (level 1). Those records deemed
to be ‘included’ or ‘unclear’ will automatically pass to the
next level of screening (level 2). However, if the record is
deemed ‘excluded’, then it needs to be reviewed by a sec-
ond reviewer to confirm exclusion. This process is
referred to as liberal accelerated screening, a more effi-
cient means of initially assessing records for relevancy.
Second, full text screening will be performed inde-
pendently by two reviewers and discordance will be
resolved first by consensus and then by third member of
the research team, as needed (level 2 assessment). The
selection process and reasons for exclusion will be docu-
mented using the PRISMA flow diagram [32].
Literature search results will be uploaded to Distiller
Systematic Review Software (DSR), an Internet-based soft-
ware program that facilitates collaboration among
reviewers during the study selection process. The team will
develop and test screening questions and forms for level 1
and 2 assessments based on the inclusion and exclusion
criteria. Citation abstracts and full text articles will be
uploaded with screening questions to DSR. Prior to the
formal screening process, a calibration exercise will be
undertaken to pilot and refine the screening questions.
Further, we will provide training to new members of the
review team not familiar with the DSR software and the
content area prior to the start of the review.
Data abstraction
Two independent reviewers will extract and document
the content of each included study using a standardized
data abstraction form in DSR to capture information on
the descriptive and quantitative characteristics of individ-
ual studies. Useful data to collect will include:
1. publication details (for example, year of publication,
language of publication, country in which the study
was conducted, publication status, sources of
funding);
2. substance targeted by the BI;
3. study details (for example, date, number of centers,
follow-up);4. study design methodology (for example, methods of
allocation, blinding) for conducting a risk of bias
assessment;
5. population details of the target group (for example,
sample size, characteristics such as age, sex and
ethnic background);
6. details on the screening method used to determine
who should be provided a BI (for example, nature of
method, whether validated, administration method,
length to screen, type of professional conducting the
screening, the extent of training they received in
conducting screening);
7. details of the intervention and comparison groups,
including any theoretical frameworks and intensity of
the intervention (for example, length of and time
between sessions);
8. fidelity of the intervention;
9. setting;
10. outcome details including definitions, outcome
measures used and data.
Disagreements will be resolved first by consensus and
then by a third member of the research team, as needed.
Prior to performing data abstraction, the review team
will refine the development of the extraction forms and
will conduct a calibration and training exercise.
Assessing the risk of bias
Two independent reviewers will assess the risk of bias
for each included study. Any disagreements will be
resolved first through discussion and then by third mem-
ber of the research team, as needed. Determining risk of
bias summary assessments for outcomes will follow that
proposed by The Cochrane Collaboration [33] and incor-
porated into grading the quality of evidence.
All RCTs will be assessed using the Cochrane Risk of
Bias (RoB) tool [33]. The Cochrane RoB tool evaluates
seven domains (sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of
outcome assessors, incomplete outcome data, selective
outcome reporting, and other sources of bias). Other
sources of bias will include single versus multicenter stud-
ies and study sponsorship. We will also assess cluster ran-
domized trials for the possibility of recruitment bias [34].
If included, other study designs will be critically appraised
with the Cochrane Effective Practice and Organisation of
Care group’s modified RoB tool (Appendix 2) [29].
Unit of analysis issues
For studies whose allocation design is a group level (for
example, schools) and yet analyzed at the individual level
(for example, students), ‘unit of analysis’ errors can occur,
whereby results can be overly precise and contribute
greater weight in a meta-analysis. Where possible, we
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relation coefficient to address these errors [35], prefer-
ably with empirically-derived values.
Missing data
If information or data is missing or incomplete, we will
attempt to contact the study authors twice over four
weeks by email. We will analyze data as close to the
intention-to-treat principle (all participants analyzed
according to assigned treatment group) as possible. If
loss to follow-up occurs, we will incorporate any add-
itional data provided in study reports or by the authors;
we will not impute data for any outcomes.
Evidence synthesis
Study characteristics will be summarized narratively in the
text, and/or summary tables in the report; such data may
be presented as frequencies and percentages, medians and
interquartile ranges, or means and standard deviations,
where appropriate. For outcomes, where appropriate and
possible (depending on the quantity, quality, and statistical
and clinical homogeneity of the available data), pooled esti-
mates of intervention efficacy or effectiveness will be com-
puted using standard meta-analytic methods [36]. Random
effects models will be used for all meta-analyses. A narra-
tive synthesis of the evidence will be conducted when
quantitative pooling of data is not possible.
Main analyses
For the primary analysis, our intent is to evaluate all BIs for
all drug classes together. We are uncertain what exists in
the literature regarding how interventions are targeted (that
is, for general drug use or for specific drugs), and we do
not know how varied they may be in study characteristics
or methodology. Before proceeding with a pooled analysis,
we will determine whether studies are homogeneous with
respect to those characteristics. If too much heterogeneity
exists, we will not meta-analyze all studies together. In
addition, should considerable statistical heterogeneity
(≥75%) exist, we will also not present a pooled analysis.
We will also conduct subgroup analyses according to
drug class (for example, cannabinoids, opioids and amphe-
tamines, with general use as a separate category) and inter-
vention setting (for example, school, hospital, community).
Dichotomous outcomes
For dichotomous outcomes, the risk ratio and 95% confi-
dence intervals will be presented. The unit of analysis is
the proportion of study participants with the outcome
for intervention and control groups.
Continuous outcomes
For continuous outcomes, mean differences and 95%
confidence intervals will be used for outcomes reportedon similar scales or with similar measures; standardized
mean differences will be used where continuous out-
comes are reported using different scales or measures.
Transformation of data to allow analyses with mean dif-
ferences will be made wherever possible. Where change-
from-baseline data are reported in the studies, we will
extract in addition to post-intervention data.
Ordinal outcomes
Decisions about handling and analyzing ordinal out-
comes will be determined post hoc, subject to the body
of evidence available.
Time-to-event data
For time-to-event data, the generic inverse variance
method will be used to meta-analyze outcomes using
log hazard ratios and standard errors; the Parmar
method [37] will be used to estimate data, as needed.
Other statistical considerations
Data conversions Where needed, we will convert data
(for example, standard error to standard deviation) for
use in analyses and to facilitate consistent presentation
of results across studies.
Interrupted time series designs If interrupted time
series studies are included we will re-analyze data,
where needed and if feasible, for change in level and
slope according to time series regression analyses
[38].
Statistical heterogeneity
Statistical heterogeneity will be evaluated using
I-squared (I2) statistics; for the interpretation of I2, a
rough guide of low (0% to 25%), moderate (25% to
50%), substantial (50% to 75%), and considerable (75%
to 100%) heterogeneity will be used [36,38]. Possible
reasons contributing to heterogeneity will be explored.
Exploring statistical heterogeneity
If studies are determined to be statistically heterogeneous,
we will conduct the following subgroup analyses, where
possible:
1. age of participants (12 to 18 years, 19 to 24 years,
25 years or greater);
2. sex;
3. description of screening method (well-described,
poorly described, unclear screening method);
4. type of intervention provided (for example, cognitive
behavioral therapy, motivational enhancement
therapy, motivational interviewing);
5. type of practitioner.
Appendices
Appendix 1. Proposed MEDLINE search strategy
1. SBIRT.tw.
2. (SBI or SBIs).tw.
3. exp Substance Abuse Detection/
4. ((substance* adj2 test*) or (substance* adj2 detect*)
or (substance* adj2 screen*) or (drug* adj2 detect*)
or (drug* adj2 screen*) or (drug* adj2 test*)).tw.
5. 3 or 4
6. Substance-Related Disorders/
7. exp Amphetamine-Related Disorders/
8. exp Cocaine-Related Disorders/
9. exp Marijuana Abuse/or exp Marijuana Smoking/
10. exp Opioid-Related Disorders/
11. exp Phencyclidine Abuse/
12. Psychoses, Substance-Induced/
13. exp Substance Abuse, Intravenous/
14. ((substance-related or substance-induced)
adj3 (disorder* or psychosis or psychoses)).tw.
15. ((drug or drugs or substance* or opioid* or opiate* or
amphetamine* or amfetamine* or methamphetamine*
or methamfetamine or benzodiazepine* or morphine*
or methadone* or prescription* or phencyclidine* or
solvent* or barbiturate* or depressant* or stimulant* or
psychotherap* or psycho-therap* or steroid*) adj3
(addict* or abuse* or abusing or abusive or misuse* or
mis-use* or misusing or mis-using or illicit* or illegal*
or unlawful* or unsanction* or habit* or dependen* or
disorder or disorders or relapse* or consumption)).tw.
16. or/6-15
17. Dextropropoxyphene/
18. (Dextropropoxyphene or D-Propoxyphene
or Propoxyphene or Darvon or Vicodin).tw.
19. Hydromorphone/
20. (Hydromorphon* or Dihydromorphinone
or Dilaudid or Laudacon or Palladone).tw.
21. exp Meperidine/
22. (Meperidine or Demerol or Dolantin or Dolargan or
Dolcontral or Dolin or Dolosal or Dolsin or Isonipecain
or Lidol or Lydol or Operidine or Pethidine or
Promedol or Dimethylmeperidine or Isopromedol or
Trimeperidine or Lomotil or Reasec).tw.
23. Pentobarbital/
24. (Pentobarbital or Diabutal or Etaminal or Ethaminal or
Mebubarbital or Mebumal or Nembutal or
Pentobarbitone or Sagatal).tw.
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will verify results of the subgroup analyses with univari-
able meta-regression. The variables outlined above for
subgroup analyses will be considered statistically signifi-
cant at P <0.01.
Sensitivity analyses
If data permit, and where needed, sensitivity analyses
may be undertaken regarding the risk of bias (restricting
the analyses to studies with low risk of bias), the fidelity
of the intervention, data issues and measurement of out-
comes or to explore reasons for heterogeneity.
Test for funnel plot asymmetry
If at least 10 studies are included in a given meta-ana-
lysis, we will evaluate for funnel plot asymmetry, depend-
ing on the outcome, and postulate reasons for the
asymmetry (for example, publication bias) [39-41].
Grading the quality of evidence
The quality of evidence for all outcomes will be judged
using the Grading of Recommendations Assessment, De-
velopment and Evaluation working group methodology
[41]. The quality of evidence will be assessed across the
domains of risk of bias, consistency, directness, precision
and publication bias. Additional domains may be consid-
ered where appropriate. Quality will be adjudicated as
high (further research is very unlikely to change our con-
fidence in the estimate of effect), moderate (further re-
search is likely to have an important impact on our
confidence in the estimate of effect and may change the
estimate), low (further research is very likely to have an
important impact on our confidence in the estimate of
effect and is likely to change the estimate), or very low
(very uncertain about the estimate of effect).
Quality assurance
We will discuss results in light of the strength of findings
as well as their research and practice implications. This
review will be reported according to the PRISMA state-
ment [32] and using the assessment of multiple system-
atic reviews tool for additional quality control [42].
Discussion
The accumulating research assessing the effectiveness of
SBIRT for the non-medical use of psychoactive substances
underscores the need for a systematic review in order to
assist clinicians and others to inform evidence-based prac-
tice. The results from a recent evidence map of systematic
reviews to inform the prevention, treatment and/or harm
reduction for illicit drug use [43] revealed no published
systematic reviews or meta-analyses on the effectiveness of
the SBIRT model in reducing illicit drug use. A systematic
review will yield a better understanding of the effectivenessof BIs as part of SBIRT aimed at the non-medical use of
psychoactive substances, which will be helpful in establish-
ing guidelines for implementation in general practice and
other relevant settings. Finally, synthesizing the evidence
base may provide guidance as to where future research
might be most beneficial.
25. exp Diazepam/
26. (Diazepam or Apaurin or Diazemuls or Faustan or
Relanium or Seduxen or Sibazon or Stesolid or Valium
or Nordazepam or Calmday or Dealkylprazepam or
Demethyldiazepam or Deoxydemoxepam or
Desmethyldiazepam or Nordaz or Nordiazepam or
Norprazepam or "Tranxilium N" or Vegesan).tw.
27. ("substance use" or "substance usage").tw.
28. Alprazolam/
29. (Alprazolam or Alprazolan or Alprox or "Apo-
Alpraz" or Cassadan or Esparon or Kalma or "Novo-
Alprazol" or "Nu-Alpraz" or Ralozam or Tafil or
Trankimazin or Xanax).tw.
30. Dextroamphetamine/
31. (Dextroamphetamine or Curban or
"d-Amphetamine" or Dexamfetamine or
Dexamphetamine or Dexedrine or dextro-
Amphetamine or DextroStat or Oxydess).tw.
32. Methylphenidate/
33. (Methylphenidate or Centedrin or Daytrana or
Dexmethylphenidate or Equasym or Focalin or
Metadate or Methylin or Phenidylate or Ritalin* or
Tsentedrin or Adderall or Obetrol).tw.
34. or/17-33
35. 34 and (addict* or abuse* or abusing or abusive or
misuse* or mis-use* or misusing or mis-using or
illicit* or illegal* or unlawful* or unsanction*).tw.
36. 16 or 35
37. exp designer drugs/or exp street drugs/
38. (designer drug$1 or street drug$1 or recreational
drug$1 or narcotic* or non-therapeutic drug$1 or
non-medical drug$1).tw.
39. exp Cannabis/
40. (Cannabi* or marijuana or marihuana or hemp or
hash or hashish or ganja).tw.
41. exp Heroin/
42. (Heroin or Diacetylmorphine or Diagesil
or Diamorphine or Diamorf or speed).tw.
43. exp Cocaine/
44. (cocaine or crack).tw.
45. exp Hallucinogens/
46. (hallucinogen* or psychedelic*).tw.
47. exp amphetamine/or exp methamphetamine/or exp
n-methyl-3,4-methylenedioxyamphetamine/or
mescaline/or ketamine/or oxycodone/
48. (methylenedioxymethamphetamine or MDMA or
ecstasy or methamphetamine or crystal meth or
mescaline or mezcalin or peyote or
trimethoxyphenethylamine or ketamine or Calipsol or
Calypsol or "CI-581" or Kalipsol or Ketalar or Ketanest
or Ketaset or "special k" or mushroom* or prilocybin or
oxycodone* or oxycontin* or
dihydrohydroxycodeinone or dihydrone or dinarkon or
eucodal or oxiconum or oxycodeinon or oxycone or
pancodine or theocodin or "gamma hydroxybutrate" or
GHB or PCP).tw.
49. ((sniff* or inhal* or snort*) adj3 (solvent* or glue or
drug or drugs)).tw.
50. ("inhalant use" or "inhalant usage").tw.
51. exp Lysergic Acid Diethylamide/
52. (LSD or Lysergide or Lysergic Acid Diethylamide).tw.
53. ("drug use" or "drug usage" or (drug adj user*)).tw.
54. or/37-53




59. (detect* or disclos* or identif* or question* or reveal*
or survey* or unveil*).tw.
60. Interview, Psychological/
61. ((interview* or encounter* or visit*) adj3 (counsellor*
or counselor* or nurse* or physician* or doctor* or
clinician* or psychologi* or social worker*)).tw.
62. or/56-61
63. 55 and 62
64. 5 or 63
65. Psychotherapy, Brief/or Crisis Intervention/
66. (brief intervention* or brief prevention*).tw.
67. 65 or 66
68. exp Motivation/
69. exp Psychotherapy/
70. (psycho-therap* or psychotherap*).tw.
71. ((cogniti* or behavior* or behaviour* or conditioning
or motivation* or psychosocial* or psycho-social* or
psychological) adj3 (therapy or therapies or
therapeutic or interven* or modify or modifies or
modified or modification)).tw.
72. (counselling or counseling).tw.
73. or/68-72
74. (brief* or short* or short-rang* or short-term or
abbreviate* or concise or limited or time-limited or
crisis or crises or immediate*).tw.
75. 73 and 74
76. 67 or 75
77. exp "Referral and Consultation"/
78. (refer or refers or referral* or gatekeeper* or
gate-keeper* or specialist* or specialty).tw.
79. 77 or 78
80. 64 and (76 or 79)
81. 1 or 2 or 80
82. limit 81 to "reviews (specificity)"
83. meta analysis.pt.
84. exp meta-analysis as topic/
85. (meta-analy* or metanaly* or metaanaly* or met
analy* or integrative research or integrative
review* or integrative overview* or research
integration or research overview* or collaborative
review*).ti,ab.
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86. (systematic review* or systematic overview*
or technology assessment* or HTA or HTAs).ti,ab.
87. exp Technology assessment, biomedical/
88. health technology assessment winchester england.jn.
89. (evidence report technology assessment or evidence
report technology assessment summary).jn.
90. or/83-89
91. 81 and 90
92. 82 or 91
93. (controlled clinical trial or randomized controlled trial).pt.
94. exp RCTs as topic/or exp controlled clinical trials as
topic/or exp random allocation/or exp double-blind
method/or exp single-blind method/or exp placebos/
95. "controlled clinical trial".tw.
96. (random* or RCT$1 or placebo*).tw.
97. ((singl* or doubl* or trebl* or tripl*) and (mask* or
blind* or dumm*)).tw.
98. or/93-97
99. 81 and 98
100. clinical trial.pt.
101. exp Clinical Trials as Topic/
102. "clinical trial".ti,ab.
103. (volunteer or volunteers or open label*
or nonrandom* or non random* or quasirandom*
or quasi-random*).tw.
104. exp Cohort Studies/or exp Longitudinal Studies/or
exp Prospective Studies/or exp Follow-Up Studies/
105. (cohort or cohorts or longitudinal or prospective).tw.
106. ((observational or follow-up or followup) adj stud*).tw.
107. (population-based stud* or population-based
analys* or population stud* or population analys*).tw.
108. ((descriptive adj stud*) or (multidimensional
adj stud*) or (multi-dimensional adj stud*) or
(multicenter adj stud*) or (multi-center adj stud*) or
(multicentr* adj stud*) or (multi-centr* adj stud*)).tw.
109. exp Multicenter Study/or exp Multicenter Studies
as Topic/
110. Comparative Study.pt.
111. ((comparative adj study) or (comparative adj
studies) or "before and after").tw.
112. or/100-111
113. 81 and 111
114. 92 or 99 or 113
Appendix 2. Cochrane Effective Practice and Organisa-
tion of Care Review group’s criteria for assessing risk of
bias in non-randomized, controlled before-and-after, and
interrupted time series studies
Non-randomized controlled trials and controlled before-after
studies
 Was the allocation sequence adequately generated?
 Was the allocation adequately concealed?
 Were baseline outcome measurements similar?
 Were baseline characteristics similar?
 Were incomplete outcome data adequately
addressed?
 Was knowledge of the allocated interventions
adequately prevented during the study?
 Was the study adequately protected against
contamination?
 Was the study free from selective outcome
reporting?
 Was the study free from other risks of bias?
Interrupted time series studies
 Was the intervention independent of other changes?
 Was the shape of the intervention effect
prespecified?
 Was the intervention unlikely to affect data
collection?
 Was knowledge of the allocated interventions
adequately prevented during the study?
 Were incomplete outcome data adequately
addressed?
 Was the study free from selective outcome
reporting?
 Was the study free from other risks of bias?
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